Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Gastrointest Surg. 2013 Jan;17(1):66-77; discussion p.77. doi: 10.1007/s11605-012-2005-4. Epub 2012 Sep 5.
Advances in the surgical management of hepatocellular carcinoma (HCC) have expanded the indications for curative hepatectomy, including more extensive liver resections. The purpose of this study was to examine long-term survival trends for patients treated with major hepatectomy for HCC.
Clinicopathologic data for 1,115 patients with HCC who underwent hepatectomy between 1981 and 2008 at five hepatobiliary centers in France, China, and the USA were assessed. In addition to other performance metrics, outcomes were evaluated using resection of ≥4 liver segments as a novel definition of major hepatectomy.
Major hepatectomy was performed in 539 patients. In the major hepatectomy group, median tumor size was 10 cm (range: 1-27 cm) and 22 % of the patients had bilateral lesions. The TNM Stage distribution included 29 % Stage I, 31 % Stage II, 38 % Stage III, and 2 % Stage IV. The postoperative histologic examination indicated that chronic liver disease was present in 35 % of the patients and tumor microvascular invasion was identified in 60 % of the patients. The 90-day postoperative mortality rate was 4 %. After a median follow-up time of 63 months, the 5-year overall survival rate was 40 %. Patients treated with right hepatectomy (n = 332) and those requiring extended hepatectomy (n = 207) had similar 90-day postoperative mortality rates (4 % and 4 %, respectively, p = 0.976) and 5-year overall survival rates (42 % and 36 %, respectively, p = 0.523). Postoperative mortality and overall survival rates after major hepatectomy were similar among the participating countries (p > 0.1) and improved over time with 5-year survival rates of 30 %, 40 %, and 51 % for the years 1981-1989, 1990-1999, and the most recent era of 2000-2008, respectively (p = 0.004). In multivariate analysis, factors that were significantly associated with worse survivals included AFP level >1,000 ng/mL, tumor size >5 cm, presence of major vascular invasion, presence of extrahepatic metastases, positive surgical margins, and earlier time period in which the major hepatectomy was performed.
This multinational, long-term HCC survival analysis indicates that expansion of surgical indications to include major hepatectomy is justified by the significant improvement in outcomes over the past three decades observed in both the East and the West.
肝细胞癌(HCC)的外科治疗进展扩大了根治性肝切除术的适应证,包括更广泛的肝切除术。本研究的目的是研究接受主要肝切除术治疗 HCC 的患者的长期生存趋势。
评估了 1981 年至 2008 年在法国、中国和美国的五个肝胆中心接受肝切除术的 1115 例 HCC 患者的临床病理数据。除其他表现指标外,还使用切除≥4 个肝段作为主要肝切除术的新定义来评估结果。
539 例患者接受了主要肝切除术。在主要肝切除术组中,肿瘤最大直径为 10cm(范围:1-27cm),22%的患者有双侧病变。TNM 分期包括 29%的 I 期、31%的 II 期、38%的 III 期和 2%的 IV 期。术后组织学检查显示 35%的患者存在慢性肝病,60%的患者存在肿瘤微血管侵犯。90 天术后死亡率为 4%。中位随访 63 个月后,5 年总生存率为 40%。接受右半肝切除术(n=332)和需要扩大肝切除术(n=207)的患者 90 天术后死亡率相似(分别为 4%和 4%,p=0.976)和 5 年总生存率(分别为 42%和 36%,p=0.523)。主要肝切除术的术后死亡率和总生存率在参与国家之间相似(p>0.1),并且随着时间的推移而改善,1981-1989 年、1990-1999 年和 2000-2008 年最近的时期的 5 年生存率分别为 30%、40%和 51%(p=0.004)。多因素分析显示,与生存不良显著相关的因素包括 AFP 水平>1000ng/ml、肿瘤直径>5cm、存在大血管侵犯、存在肝外转移、切缘阳性和主要肝切除术进行的时间更早。
这项多国 HCC 生存分析表明,过去三十年在东西方观察到的结果显著改善,将手术适应证扩大到包括主要肝切除术是合理的。